http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 10 Mar 2026 16:58:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Telix+Pharmaceuticals+++++For%3A+Mar+09/26140390.html si-local-file:///var/storage/secattach/20260310/26140390.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Telix+Pharmaceuticals+++++For%3A+Mar+09/26140390.html Tue, 10 Mar 2026 16:58:00 -0400 O.31276474 TLX TLX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Telix+Pharmaceuticals+++++For%3A+Mar+09/26140390.html si-local-file:///var/storage/secattach/20260310/26140390.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Telix+Pharmaceuticals+++++For%3A+Mar+09/26140390.html Tue, 10 Mar 2026 16:58:00 -0400 O.31276474 TLX TLX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Telix+Pharmaceuticals+++++For%3A+Mar+09/26140390.html si-local-file:///var/storage/secattach/20260310/26140390.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Telix+Pharmaceuticals+++++For%3A+Mar+09/26140390.html Tue, 10 Mar 2026 16:58:00 -0400 O.31276474 TLX TLX http://www.streetinsider.com/FDA/Telix+reports+positive+Phase+3+Part+1+results+for+prostate+cancer+drug/26133792.html <p>Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) announced that Part 1 of its ProstACT Global Phase 3 study for TLX591-Tx achieved primary objectives, demonstrating acceptable safety and tolerability for the prostate cancer treatment.</p> <p>The study tested TLX591-Tx, a lutetium-177 radio antibody-drug conjugate therapy, in 36 patients with metastatic castration resistant prostate cancer. Patients received the drug in combination with standard treatments including abiraterone, enzalutamide, or docetaxel.</p> <p>Key findings showed no new safety signals, with all patients completing both doses as planned. The most common side effects were fatigue affecting 53% of patients, nausea in 28%, and dry mouth in 25%. Blood-related side http://www.streetinsider.com/FDA/Telix+reports+positive+Phase+3+Part+1+results+for+prostate+cancer+drug/26133792.html Mon, 09 Mar 2026 19:20:14 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX http://www.streetinsider.com/FDA/Telix+reports+positive+Phase+3+Part+1+results+for+prostate+cancer+drug/26133792.html <p>Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) announced that Part 1 of its ProstACT Global Phase 3 study for TLX591-Tx achieved primary objectives, demonstrating acceptable safety and tolerability for the prostate cancer treatment.</p> <p>The study tested TLX591-Tx, a lutetium-177 radio antibody-drug conjugate therapy, in 36 patients with metastatic castration resistant prostate cancer. Patients received the drug in combination with standard treatments including abiraterone, enzalutamide, or docetaxel.</p> <p>Key findings showed no new safety signals, with all patients completing both doses as planned. The most common side effects were fatigue affecting 53% of patients, nausea in 28%, and dry mouth in 25%. Blood-related side http://www.streetinsider.com/FDA/Telix+reports+positive+Phase+3+Part+1+results+for+prostate+cancer+drug/26133792.html Mon, 09 Mar 2026 19:20:14 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX http://www.streetinsider.com/FDA/Telix+reports+positive+Phase+3+Part+1+results+for+prostate+cancer+drug/26133792.html <p>Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) announced that Part 1 of its ProstACT Global Phase 3 study for TLX591-Tx achieved primary objectives, demonstrating acceptable safety and tolerability for the prostate cancer treatment.</p> <p>The study tested TLX591-Tx, a lutetium-177 radio antibody-drug conjugate therapy, in 36 patients with metastatic castration resistant prostate cancer. Patients received the drug in combination with standard treatments including abiraterone, enzalutamide, or docetaxel.</p> <p>Key findings showed no new safety signals, with all patients completing both doses as planned. The most common side effects were fatigue affecting 53% of patients, nausea in 28%, and dry mouth in 25%. Blood-related side http://www.streetinsider.com/FDA/Telix+reports+positive+Phase+3+Part+1+results+for+prostate+cancer+drug/26133792.html Mon, 09 Mar 2026 19:20:14 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX http://www.streetinsider.com/FDA/Telix+reports+positive+Phase+3+Part+1+results+for+prostate+cancer+drug/26133792.html <p>Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) announced that Part 1 of its ProstACT Global Phase 3 study for TLX591-Tx achieved primary objectives, demonstrating acceptable safety and tolerability for the prostate cancer treatment.</p> <p>The study tested TLX591-Tx, a lutetium-177 radio antibody-drug conjugate therapy, in 36 patients with metastatic castration resistant prostate cancer. Patients received the drug in combination with standard treatments including abiraterone, enzalutamide, or docetaxel.</p> <p>Key findings showed no new safety signals, with all patients completing both doses as planned. The most common side effects were fatigue affecting 53% of patients, nausea in 28%, and dry mouth in 25%. Blood-related side http://www.streetinsider.com/FDA/Telix+reports+positive+Phase+3+Part+1+results+for+prostate+cancer+drug/26133792.html Mon, 09 Mar 2026 19:20:14 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX http://www.streetinsider.com/FDA/Telix+reports+positive+Phase+3+Part+1+results+for+prostate+cancer+drug/26133792.html <p>Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) announced that Part 1 of its ProstACT Global Phase 3 study for TLX591-Tx achieved primary objectives, demonstrating acceptable safety and tolerability for the prostate cancer treatment.</p> <p>The study tested TLX591-Tx, a lutetium-177 radio antibody-drug conjugate therapy, in 36 patients with metastatic castration resistant prostate cancer. Patients received the drug in combination with standard treatments including abiraterone, enzalutamide, or docetaxel.</p> <p>Key findings showed no new safety signals, with all patients completing both doses as planned. The most common side effects were fatigue affecting 53% of patients, nausea in 28%, and dry mouth in 25%. Blood-related side http://www.streetinsider.com/FDA/Telix+reports+positive+Phase+3+Part+1+results+for+prostate+cancer+drug/26133792.html Mon, 09 Mar 2026 19:20:14 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX http://www.streetinsider.com/FDA/Telix+reports+positive+Phase+3+Part+1+results+for+prostate+cancer+drug/26133792.html <p>Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) announced that Part 1 of its ProstACT Global Phase 3 study for TLX591-Tx achieved primary objectives, demonstrating acceptable safety and tolerability for the prostate cancer treatment.</p> <p>The study tested TLX591-Tx, a lutetium-177 radio antibody-drug conjugate therapy, in 36 patients with metastatic castration resistant prostate cancer. Patients received the drug in combination with standard treatments including abiraterone, enzalutamide, or docetaxel.</p> <p>Key findings showed no new safety signals, with all patients completing both doses as planned. The most common side effects were fatigue affecting 53% of patients, nausea in 28%, and dry mouth in 25%. Blood-related side http://www.streetinsider.com/FDA/Telix+reports+positive+Phase+3+Part+1+results+for+prostate+cancer+drug/26133792.html Mon, 09 Mar 2026 19:20:14 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX http://www.streetinsider.com/FDA/Telix+reports+positive+Phase+3+Part+1+results+for+prostate+cancer+drug/26133792.html <p>Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) announced that Part 1 of its ProstACT Global Phase 3 study for TLX591-Tx achieved primary objectives, demonstrating acceptable safety and tolerability for the prostate cancer treatment.</p> <p>The study tested TLX591-Tx, a lutetium-177 radio antibody-drug conjugate therapy, in 36 patients with metastatic castration resistant prostate cancer. Patients received the drug in combination with standard treatments including abiraterone, enzalutamide, or docetaxel.</p> <p>Key findings showed no new safety signals, with all patients completing both doses as planned. The most common side effects were fatigue affecting 53% of patients, nausea in 28%, and dry mouth in 25%. Blood-related side http://www.streetinsider.com/FDA/Telix+reports+positive+Phase+3+Part+1+results+for+prostate+cancer+drug/26133792.html Mon, 09 Mar 2026 19:20:14 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX http://www.streetinsider.com/FDA/Telix+reports+positive+Phase+3+Part+1+results+for+prostate+cancer+drug/26133792.html <p>Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) announced that Part 1 of its ProstACT Global Phase 3 study for TLX591-Tx achieved primary objectives, demonstrating acceptable safety and tolerability for the prostate cancer treatment.</p> <p>The study tested TLX591-Tx, a lutetium-177 radio antibody-drug conjugate therapy, in 36 patients with metastatic castration resistant prostate cancer. Patients received the drug in combination with standard treatments including abiraterone, enzalutamide, or docetaxel.</p> <p>Key findings showed no new safety signals, with all patients completing both doses as planned. The most common side effects were fatigue affecting 53% of patients, nausea in 28%, and dry mouth in 25%. Blood-related side http://www.streetinsider.com/FDA/Telix+reports+positive+Phase+3+Part+1+results+for+prostate+cancer+drug/26133792.html Mon, 09 Mar 2026 19:20:14 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX http://www.streetinsider.com/Press+Releases/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html <ul type="disc"><li style="text-align:justify;">Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: <a target="_blank" href="https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html" rel="nofollow" target="_blank">https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html</a><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with http://www.streetinsider.com/Press+Releases/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html Mon, 09 Mar 2026 19:19:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Press+Releases/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html <ul type="disc"><li style="text-align:justify;">Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: <a target="_blank" href="https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html" rel="nofollow" target="_blank">https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html</a><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with http://www.streetinsider.com/Press+Releases/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html Mon, 09 Mar 2026 19:19:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Press+Releases/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html <ul type="disc"><li style="text-align:justify;">Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: <a target="_blank" href="https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html" rel="nofollow" target="_blank">https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html</a><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with http://www.streetinsider.com/Press+Releases/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html Mon, 09 Mar 2026 19:19:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Press+Releases/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html <ul type="disc"><li style="text-align:justify;">Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: <a target="_blank" href="https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html" rel="nofollow" target="_blank">https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html</a><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with http://www.streetinsider.com/Press+Releases/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html Mon, 09 Mar 2026 19:19:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Press+Releases/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html <ul type="disc"><li style="text-align:justify;">Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: <a target="_blank" href="https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html" rel="nofollow" target="_blank">https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html</a><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with http://www.streetinsider.com/Press+Releases/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html Mon, 09 Mar 2026 19:19:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Press+Releases/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html <ul type="disc"><li style="text-align:justify;">Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: <a target="_blank" href="https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html" rel="nofollow" target="_blank">https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html</a><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with http://www.streetinsider.com/Press+Releases/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html Mon, 09 Mar 2026 19:19:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Press+Releases/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html <ul type="disc"><li style="text-align:justify;">Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: <a target="_blank" href="https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html" rel="nofollow" target="_blank">https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html</a><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with http://www.streetinsider.com/Press+Releases/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html Mon, 09 Mar 2026 19:19:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Press+Releases/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html <ul type="disc"><li style="text-align:justify;">Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: <a target="_blank" href="https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html" rel="nofollow" target="_blank">https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html</a><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with http://www.streetinsider.com/Press+Releases/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html Mon, 09 Mar 2026 19:19:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Press+Releases/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html <ul type="disc"><li style="text-align:justify;">Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: <a target="_blank" href="https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html" rel="nofollow" target="_blank">https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html</a><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with http://www.streetinsider.com/Press+Releases/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html Mon, 09 Mar 2026 19:19:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Globe+Newswire/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html <ul type="disc"><li style="text-align:justify;">Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: <a target="_blank" href="https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html" rel="nofollow" target="_blank">https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html</a><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with http://www.streetinsider.com/Globe+Newswire/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html Mon, 09 Mar 2026 19:19:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Globe+Newswire/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html <ul type="disc"><li style="text-align:justify;">Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: <a target="_blank" href="https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html" rel="nofollow" target="_blank">https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html</a><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with http://www.streetinsider.com/Globe+Newswire/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html Mon, 09 Mar 2026 19:19:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Globe+Newswire/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html <ul type="disc"><li style="text-align:justify;">Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: <a target="_blank" href="https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html" rel="nofollow" target="_blank">https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html</a><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with http://www.streetinsider.com/Globe+Newswire/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html Mon, 09 Mar 2026 19:19:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Globe+Newswire/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html <ul type="disc"><li style="text-align:justify;">Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: <a target="_blank" href="https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html" rel="nofollow" target="_blank">https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html</a><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with http://www.streetinsider.com/Globe+Newswire/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html Mon, 09 Mar 2026 19:19:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Globe+Newswire/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html <ul type="disc"><li style="text-align:justify;">Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: <a target="_blank" href="https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html" rel="nofollow" target="_blank">https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html</a><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with http://www.streetinsider.com/Globe+Newswire/ProstACT+Global+Phase+3+Study+%28Part+1%29+Achieves+Primary+Objectives/26133787.html Mon, 09 Mar 2026 19:19:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX